Progress Of Gastrointestinal Neoplasms and Therapeutic Advances

Zhuowen Zhang

doi:10.54097/ck6nr169

Authors

Zhuowen Zhang

DOI:

https://doi.org/10.54097/ck6nr169

Keywords:

Gastrointestinal Neoplasms; Gastric Cancer; Colorectal Cancer; Immunotherapy; Microecology; Genetic Factors; Chemotherapy; Surgical Treatment; Dietary Habits; Immune Checkpoint Inhibitors.

Abstract

In recent times, there has been a notable rise in the incidence of gastrointestinal neoplasms due to changes in diet and lifestyle. When it comes to cancer-related deaths in males under 50, colorectal cancer ranks first, and in women, it is second. Gastric cancer and colorectal cancer are the two main types of intestinal neoplasms. Among East Asian populations, gastric cancer has the highest incidence rates. Studies reveal a critical role for gastrointestinal microecology in the development and course of gastrointestinal tumors. In addition to providing a brief overview of the pathophysiology and standard treatments for stomach tumors, this paper addresses the state of research regarding the connection between gastrointestinal microecology and immunological treatment of stomach tumors. The process by which gastric cancer develops is complex and involves variations in growth patterns, mucus separation, cellular structure, and genetic makeup. Microecological imbalances, genetic factors, and poor dietary practices are major causes of gastric cancer. Chemotherapy, surgery, radiation therapy, and targeted therapies are among the current treatment options. Immune checkpoint antagonists, combination immunotherapy, and adoptive immune-mediated cell therapy have all shown notable effectiveness in clinical practice. However, immunotherapy still faces obstacles from immune-related side effects and treatment resistance. Subsequent investigations will probe further into the correlation between gastrointestinal microecology and gastrointestinal tumors, presenting novel approaches to the management and avoidance of gastrointestinal neoplasms.

Downloads

Download data is not yet available.

References

Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024 [published correction appears in CA Cancer J Clin. 2024 Mar-Apr;74(2):203]. CA Cancer J Clin. 2024;74(1):12-49.

Dabing Huang, Wei Wang, Qian Shen, Bing Hu, Chushu Ji, Yifu He, Guodong Shen, Weiping Xu, Zhongliang Fang, Shilian Hu. Association between green tea consumption and gastric cancer risk in East Asian population: a Meta-analysis [J]. Chin J Clin Health,2014,17(1):30-33I0002.

Abreu MT, Peek RM Jr. Gastrointestinal malignancy and the microbiome. Gastroenterology, 2014, 146(6): 1534-1546.

Li Cheng, ZHOU Jian, QIU Jiongliang. Research progress of epidemiology and molecular biological etiology of gastric cancer. Cancer Prevention and Treatment Research,2004,31(2):115-118.

AAbdul-Latif M, Townsend K, Dearman C, Shiu KK, Khan K. Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives. Cancer Treat Rev. 2020; 88: 102030.

LIU Fumeng, Yan Liping, Li Hong et al. Progress in research on the link between eating habits and stomach cancer. Guangxi Med,2018,40(06):678-680.

Ran Z X. Etiology and pathogenesis of gastric cancer. Intermediate Medical Journal, 1995, (06):3-4.

Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature. 1998;392(6674):402-405.

Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg. 1999;230(2):170-178.

Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [published correction appears in Lancet. 2010 Oct 16;376(9749):1302]. Lancet. 2010;376(9742):687-697.

Valentini V, Cellini F. Radiotherapy in gastric cancer: a systematic review of literature and new perspectives. Expert Rev Anticancer Ther. 2007;7(10):1379-1393.

Chen Weichang, Shi Tongguo, Zhu Jinghan et al. Progress of immunotherapy for gastrointestinal tumors. Cancer Prevention and Treatment Research, 2019,49(07):639-643.

Li B, Chan HL, Chen P. Immune Checkpoint Inhibitors: Basics and Challenges. Curr Med Chem. 2019;26(17):3009-3025.

Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56-61.

Chikuma S. CTLA-4, an Essential Immune-Checkpoint for T-Cell Activation. Curr Top Microbiol Immunol. 2017; 410: 99-126.

Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275-287.

Lu H, Ma Y, Wang M, et al. B7-H3 confers resistance to Vγ9Vδ2 T cell-mediated cytotoxicity in human colon cancer cells via the STAT3/ULBP2 axis. Cancer Immunol Immunother. 2021;70(5):1213-1226.

Tam EM, Fulton RB, Sampson JF, et al. Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity. Sci Transl Med. 2019;11(512): eaax0720.

Singh S, Hassan D, Aldawsari HM, Molugulu N, Shukla R, Kesharwani P. Immune checkpoint inhibitors: a promising anticancer therapy. Drug Discov Today. 2020;25(1):223-229.

Feldman SA, Assadipour Y, Kriley I, Goff SL, Rosenberg SA. Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors. Semin Oncol. 2015;42(4):626-639.

MAO C Y (Review), Cong H (review). Application of PD-1 inhibitors in immunotherapy of gastric cancer. Lab Med & Clin, 2021,21(3):410-413.